Translational Studies and Clinical Pharmacology of New Drugs for Chemoprevention

化学预防新药的转化研究和临床药理学

• 批准号: 8689936
• 负责人: STEVEN P STRATTON
• 金额: $ 5.18万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8689936
• 关键词: Actinic keratosis; Biological Markers; Biology; Cancer Etiology; Carcinoma in Situ; Chemoprevention; Clinic; Clinical; Clinical Pharmacology; Clinical Research; Clinical Trials; Computer software; Data; Development; Drug Combinations; Drug Targeting; Dysplasia; Epithelial; Functional disorder; Gene Expression; Goals; Human; Image Analysis; Immunohistochemistry; Incidence; Intraepithelial Neoplasia; Lead; Lesion; Light; Link; Malignant Neoplasms; Modeling; Molecular Target; Morbidity - disease rate; Mus; Optical Coherence Tomography; Pathway interactions; Pattern; Performance; Pharmaceutical Preparations; Phase; Phosphoproteins; Pre-Clinical Model; Protein Microchips; Proteins; Proteomics; Risk; Safety; Sampling; Signal Pathway; Signal Transduction; Simulate; Skin; Skin Cancer; Skin Carcinogenesis; Squamous cell carcinoma; Sun Exposure; Testing; The Sun; Translating; UV induced; Validation; attenuation; cancer chemoprevention; cancer type; carcinogenesis; effective intervention; human FRAP1 protein; inhibitor/antagonist; insight; keratinocyte; mortality; new technology; novel therapeutics; pre-clinical; preclinical study; premalignant; prevent; programs; response; skin cancer prevention; small molecule; translational study

Project 3 will test and clinically validate mechanisms and pharmacologic strategies explored in Projects 1-2, which target Akt-mTOR, AMPK-mTOR, and Fyn/RSK pathways. Advanced clinical/translational study of skin cancer carcinogenesis, biology, and pathophysiology will help reduce morbidity/ mortality, provide insight into keratinocyte signaling, and provide an easily-accessed human model of full-spectrum carcinogenesis for other epithelial cancers. The overall goal of this Program Project is to eradicate intraepithelial neoplasias (lEN) and substantially reduce the risk of squamous cell carcinoma. Our objectives are to determine clinical, histopathologic, karyometric, and protein/phosphoprotein activation patterns associated with human skin carcinogenesis and to develop safe, active drugs for skin cancer prevention. The hypothesis for this project is that topical small molecule drugs can modulate specific targets in solar UV-induced signaling cascades resulting in attenuation or reversal of skin sun damage. Aims include; 1) To demonstrate and cross-validate signaling targets and pathways activated in chronically sun-exposed human skin; 2) To validate signaling pathway modulation demonstrated by small molecule inhibitors in preclinical studies by acutely exposing human skin to solar simulated light; 3) To demonstrate safety and tolerability of new topical drugs when applied to human skin; 4) To demonstrate biomarker and epidermal target modulation by topical drugs applied to sun-damaged human skin; and 5) To demonstrate clinical benefit of topical drugs (especially drug combinations), and further validate biomarker selection in skin cancer chemoprevention trials. Developmental Aims include: 1) To further develop optical coherence tomography hardware and discriminative image-analysis software; and 2) To develop a

项目3将测试和临床验证项目1-2中探索的机制和药理策略，这些策略针对Akt-mTOR、AMPK-mTOR和Fyn/RSK途径。皮肤癌发生、生物学和病理生理学的高级临床/翻译研究将有助于降低发病率/死亡率，提供 深入了解角质形成细胞信号，并为其他上皮性癌症提供一个容易获得的全谱致癌的人类模型。该计划项目的总体目标是根除上皮内肿瘤(LEN)，并大幅降低鳞状细胞癌的风险。我们的目标是确定临床、组织病理学、核测量和蛋白质/磷蛋白激活。 与人类皮肤癌发生相关的模式，并开发安全、有效的皮肤癌预防药物。该项目的假设是，局部小分子药物可以调节太阳紫外线诱导的信号级联中的特定靶点，从而导致皮肤日光损伤的衰减或逆转。 目的包括：1)展示和交叉验证在慢性日照下的人体皮肤中激活的信号靶点和信号通路；2)验证小分子抑制剂在临床前研究中所展示的信号通路调节，通过将人体皮肤剧烈地暴露在太阳模拟光下；3)展示 新外用药物应用于人体皮肤的安全性和耐受性；4)证明外用药物对日晒损伤皮肤的生物标志物和表皮靶点的调节作用；5)证明外用药物(特别是药物组合)的临床益处，并进一步验证生物标记物的选择 皮肤癌化学预防试验。发展目标包括：1)进一步开发光学相干层析成像硬件和鉴别图像分析软件；以及2)开发